Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Though low, this figure is three times the rate of discontinuation seen in clinical trials.
There are a variety of hepatitis C treatments offered for all genotypes, with various stages of liver damage.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
This is according to two studies of real-world use of the hepatitis C regimen.
Those who took the drug, which is included in Zepatier (grazoprevir/elbasvir), had a low rate of liver cancer during the following years.
A recent study found that transplanting such kidneys and then treating the recipient for hep C worked well.
Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
Genotype 3 of hepatitis C virus is typically difficult to treat.
More than 125,000 veterans will have received lifesaving cures by October 2018.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.